Mübarra Seğmen YILMAZ, Dilek YAVUZER, Nimet KARADAYI, Nagahan Özdemir BARIŞIK, Gözde KIR

Overin benign, ''borderline'' ve malign epitelyal tümörlerinde Ki-67 ekspresyonu ve prognostik parametrelerle ilişkisi

Amaç: Yalnızca proliferatif hücre siklusunda tesbit edilen protein yapıdaki Ki-67 antijeni tümörün büyüme hızını ve progresyonunu göstermektedir. Yaptığımız bu çalışmada; benign, borderline, malign seröz ve müsinöz over tümörlerindeki Ki-67 ekspresyonu, Ki- 67 'nin malign progresyonla ilişkisi, seröz ve müsinöz tümör tipleri arasında Ki-67'nin ekspresyonunun karşılaştırılması , Ki-67 'nin borderline ve malign tümörlerde prognostikparametre olarak anlamlılığı,serum Ca 125 diğerleri ve diğer prognostik parametrelerle ilişkisi araştırılmıştır. Materyal ve Metod: 38'i malign, 15'i borderline, 34'ü benign over tümörü ve 5'i överde endosalpingiozis tanısı almış olan toplam 92 olgunun parafin bloklarından elde edilen kesitlere Ki-67 (RTU-Ki-67 MMNovo-Castra) kullanıma hazır monoklonal antikoru immünohistokimyasal boyama prosedürü uygulandı. Bulgular: Ki-67 ile benign olguların %35,3 'ünde %1 üzerinde pozitif nükleer boyanma izlenirken, borderline olguların %80 'ninde, malign olguların ise %89,5'inde %1 üzerinde pozitif nükleer boyanma saptanmıştır.Benign,borderline,malign seröz ve müsinöz over tümörlerinde ve överde endosalpingiozis olgularında Ki-67 ekspresyonu açısından ileri derecede anlamlı farklılıklar bulunmuştur (p0,05). Malign tümörlerde Ki- 67 boyanma derecesi borderline tümörlere göre anlamlı derecede yüksek saptanmıştır (p

Anahtar Kelimeler:

Yumurtalık neoplazmları, Ki-67 antijeni, Seyir, Karsinom, CA-125 antijen

Expression of Ki-67 in bengin,borderline and malignnat epithelial tumors of the ovary, its relationship with prognostic parameters

Objektive: Ki-67 is a proteinous antigene functioning in only cell proliferation cyclus .It also indicates the tumoral growing and progression. In our study we evaluated express ion frequency of Ki-67 in benign, borderline, malign serous and mucinous tumors of ovary. Consequently we compared Ki-67 expression frequency between serous and mucinous groups, as a predictor of malign progression and as a prognostic parameter in malign and borderline tumours. Furthermore Ki-67 expressions of tumors and serum levels of Ca 125 are assesed in order to find a probable relation between them. Materials and Methods: We applied 92 parrafin sections stained with Ki-67 (RTU- Ki-67 MM Novo-Castra) ready to use monoclonal antibody immünohistochemically. These sections of 92 cases including 38 malign ,15 borderline ,34 benign ovarian tumors and 5 endosalpingiosis. Results: While 35,3% of benign cases revealed more than 1% positive nuclear staining, 80% of borderline tumors and 89,5% of malign tumors showed more than 1 % positive nuclear staining. As a result we found significant differences of Ki- 67 expression between benign, borderline, malign serous and mucinous ovarian tumors and endosalpingiosis cases(p

Keywords:

Ovarian Neoplasms, Ki-67 Antigen, Prognosis, Carcinoma, CA-125 Antigen,

PDF

___

1- Furudoi A, Tanaka S, Horuma K, et al: Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2001; 60:162-169
2-Terlikowski S, Sulkowski S, Lenczewski A, et al: Study of borderline and invasive mutinous ovarian tumors using Ki-67(MIB 1) antibodies andnucleolar organizer region (NOR) staining. Arch Gynecol Obstet 1999; 263: 29-33
3-Brustmann H: Apoptotic bodies as a morphological feature in serous ovarian carcinoma : Correlation with nüklear grade, Ki-67 and mitotic indices. Pathol Res Pract 2002; 198: 85-90
4- Darai E, Walker-Combrouze F, Dauge-Geoffroy MC, et al: Ki-67 expression in 35 borderline ovarian tumours: Relations with clinicopathologic parameters and ploidy. Eur J Obstet Gynecol ReprodBioll998; 76: 175-180
5- Heinsen CV, Meyberg R, Axt-Fliedner R, et ah immunohistochemical analysis of 1,25-Dihydroxy vitamin-D 3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma
Anticancer Research 2002; 22: 2261-2268
6- Scopa CD, Tsamandas AC, Zolota V, et ah Potential role ofbcl-2 and Ki-67 expression and apoptosis in colorectal carcinoma a clinicopathologic study. Dig Dis Sci 2003; 48: 1990-1997
7- Folpe AL, Gown AM: İmmunohistochemistry for Analysis of Soft Tissue Tumours, Chapter 8. In: Enzinger and Weiss's Soft Tissue Tumours, ed
Weiss SW, Goldblum JR, St Louis Mosby, 2001 4 thed: 199-247
8- Santos L, Amaro T, Costa C, et ah Ki-67 index enhances the prognostic accuracy of the orothelial superficial bladder carcinoma risk group classification. Int J Cancer 2003; 105: 267-272
9- oskin PJ, Sibtain A, Daley FM, et ah Glut 1 and CAIX as intrinsic markers ofhypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome ofARCON
BrJ Cancer 2003; 6:1290-1297
10-Anttila M, Kosma VM, Ji H, et ah Clinical significance of alpha catenin collogen IV, and Ki- 67 expression in epithelial ovarian cancer. J Clin Oncol 1998; 16: 2591-2600
11- Crum CP: The Female Genital Tract, Chapter 24.1n: Robbins Pathologic Basis of Disease, ed
Cotran RS, Kumar V, Collins T,W.B. Saunders Company, Tokyo,2000 6th ed.: 1035-1093
12- Clement PB: Anatomy and Histology of the Ovary, Chapter 15, Diseases of the Peritoneum, Chapter 17, Seidman JD, Rus s el P, Kurman RJ: Surface Epithelial Tumours of the Ovary, Chapter 18. In: Blaustein's Pathology of the Female Genital Tract, ed. Kurman RJ, Springer, 2002 5th ed.:649-675, 729-791, 791-905
13- Zaloudek C: Tumors of the Ovary, Chapter 13, Part C. In: Diagnostic Histopathology of Tumours , ed.Fletcher CDM, Churchill Livingstone, 2000 second ed.:567-642
14- Rosai J: Female Reproductive System, Chapter 19. In: Ackerman's Surgical Pathology, ed. Rosai J, St Louis Mosby, 1996 8th ed.: 1319-1565